Global Peripheral Vasodilator Drugs Market Analysis 2024: Size Forecast

The peripheral vasodilator drugs from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.

Peripheral Vasodilator Drugs Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.

Market Size -
The peripheral vasodilator drugs market size has grown strongly in recent years. It will grow from $5.92 billion in 2023 to $6.27 billion in 2024 at a compound annual growth rate (CAGR) of 6%. The growth in the historic period can be attributed to the shift towards less invasive surgical techniques, the demand for minimally invasive structural heart devices, ongoing training and education programs for healthcare professionals, rising healthcare expenditure, and growing patient preference for non-surgical or minimally invasive treatment options.

The peripheral vasodilator drugs market size is expected to see strong growth in the next few years. It will grow to $7.97 billion in 2028 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to the increasing aging population, growing awareness about heart health, the implementation of screening programs, favorable reimbursement policies for structural heart procedures, and timely regulatory approvals for new structural heart devices. Major trends in the forecast period include increased collaboration, real-world evidence, gene therapy, preventive interventions, and value-based healthcare.

Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/peripheral-vasodilator-drugs-global-market-report 

Scope Of Peripheral Vasodilator Drugs Market
The Business Research Company's reports encompass a wide range of information, including:

1. Market Size (Historic and Forecast): Analysis of the market's historical performance and projections for future growth.

2. Drivers: Examination of the key factors propelling market growth.

3. Trends: Identification of emerging trends and patterns shaping the market landscape.

4. Key Segments: Breakdown of the market into its primary segments and their respective performance.

5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.

6. Macro Economic Factors: Assessment of broader economic elements impacting the market.

Peripheral Vasodilator Drugs Market Overview

Market Drivers -
An increase in the prevalence of cardiovascular diseases is expected to propel the growth of the peripheral vasodilator drug market going forward. Cardiovascular diseases (CVDs) are a group of disorders affecting the heart and blood vessels, often caused by atherosclerosis, leading to conditions like heart attacks, strokes, hypertension, and heart failure. The cases of cardiovascular diseases arise primarily due to sedentary lifestyles, unhealthy diets, aging populations, rising rates of obesity, and related health conditions such as diabetes and hypertension. Peripheral vasodilators in cardiovascular diseases improve blood flow, reduce blood pressure, decrease the heart’s workload, and alleviate symptoms of conditions such as peripheral arterial disease. For instance, in January 2024, according to an article published by the American Heart Association, a US-based nonprofit organization focused on cardiovascular medical research, cardiovascular disease caused 931,578 deaths in the US, slightly more than the 928,741 in 2020. Globally, there were 19.91 million CVD deaths in 2021, compared to 19.05 million in 2020. Therefore, the increase in the prevalence of cardiovascular diseases is driving the growth of the peripheral vasodilator drug market.

Market Trends -
Major companies operating in the peripheral vasodilator drugs market are focusing on drug development with triple-drug combination therapies to optimize treatment outcomes and expand market share in cardiovascular therapeutics. Triple-drug combination therapy is an antihypertensive FDC that targets patients who have not achieved adequate blood pressure control with dual-drug therapies or are unable to tolerate diuretic-based combinations. For instance, in August 2023, Ajanta Pharma Limited, an India-based pharmaceutical company specializing in cardiology, introduced Met XL AMT, a novel triple-drug combination to manage hypertension among Indian patients. It is a fixed-dose combination (FDC) of three antihypertensive agents, including Telmisartan, Amlodipine, and Metoprolol. These agents work together to lower blood pressure by relaxing blood vessels, which is a characteristic of peripheral vasodilators. The drug is specifically approved by DCGI for managing uncontrolled hypertension alongside stable coronary artery disease, making it the world's first fixed-dose combination (FDC) of metoprolol succinate (extended-release) 50 mg, amlodipine 5 mg, and telmisartan 40 mg.

The peripheral vasodilator drugs market covered in this report is segmented –

1) By Drug Type: Calcium Channel Blockers, Direct-Acting Vasodilators, Alpha-Adrenergic Blockers, Potassium Channel Activators, Nitrates, Other Types
2) By Indication: Hypertension, Angina, Heart Failure, Other Indications
3) By Application: Hospital, Retail Pharmacies, Other Applications

Get an inside scoop of the peripheral vasodilator drugs market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=16508&type=smp 

Regional Insights -
North America was the largest region in the peripheral vasodilator drugs market in 2023. The regions covered in the peripheral vasodilator drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Key Companies -
Major companies operating in the peripheral vasodilator drugs market are Pfizer Inc., Bayer AG, Sanofi S.A., Thermo Fisher Scientific Inc., AstraZeneca PLC, Abbott Laboratories, Novartis AG, GSK plc, Takeda Pharmaceutical Company, Gilead Sciences Inc, Amgen Inc, Boehringer Ingelheim International GmbH, Merck & Co, Viatris Inc., Baxter, Teva Pharmaceutical Industries, Astellas Pharma, Daiichi Sankyo Company, Limited, Sun Pharmaceutical Industries, Mitsubishi Tanabe Pharma, Cipla Limited, Hikma Pharmaceuticals, Lupin Pharmaceuticals, Glenmark Pharmaceuticals Ltd, Torrent Pharmaceuticals, Ipca Laboratories, Alembic Pharmaceuticals

Table of Contents

1. Executive Summary
2. Peripheral Vasodilator Drugs Market Report Structure
3. Peripheral Vasodilator Drugs Market Trends And Strategies
4. Peripheral Vasodilator Drugs Market – Macro Economic Scenario
5. Global Peripheral Vasodilator Drugs Market Size and Growth
.
.
.
32. Global Peripheral Vasodilator Drugs Market Competitive Benchmarking
33. Global Peripheral Vasodilator Drugs Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Peripheral Vasodilator Drugs Market
35. Peripheral Vasodilator Drugs Market Future Outlook and Potential Analysis
36. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info 

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company 
Twitter: https://twitter.com/tbrc_info 
Facebook: https://www.facebook.com/TheBusinessResearchCompany 
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ 
Blog: https://blog.tbrc.info/ 
Healthcare Blog: https://healthcareresearchreports.com/ 
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model